FVR vs REGN · rev $15.2M vs P/E 14, rev $14.34B
FrontView REIT, Inc. (FVR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
FrontView REIT, Inc. (FVR) is a reit - diversified company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported FVR revenue for 2024-12-31 was $15.2M. Net income was -$4.8M. Revenue was down 66.1% from 2024-10-02 to 2024-12-31. FVR currently screens at market cap $281.0M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FVR currently screens at market cap $281.0M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FVR and REGN stock pages for the full models.
Not investment advice.